A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Immunosuppressants lead to an increased risk of infection, but few prospective studies have assessed the incidence of opportunistic infections in inflammatory bowel disease (IBD) patients, a high proportion of whom are treated with immunosuppressants. The aim of this study was to assess the age distribution of Japanese IBD patients with opportunistic infections and the risk factors associated with these infections.
A multicenter, prospective study of 570 IBD patients was conducted. The patients were followed for up to 12 months to identify any new infections. The incidence of opportunistic infections and the age distribution of patients with these infections were analyzed. We carried out a case–control study in which 2 non-infected IBD patients were selected as controls for each case (infected IBD patient); the effect of medications on the infection rate was also examined.
Fifty-two (9.1 %) of 570 IBD patients developed opportunistic infections. Herpes simplex virus and herpes zoster virus infections were observed in 29 and 16 patients, respectively. No cases of active tuberculosis were observed. The incidence of opportunistic infections in patients aged 50 years or over was significantly higher than that in the other age groups (p = 0.01). The use of steroids (p = 0.02), thiopurine (p < 0.01), and immunosuppressant combination therapy (p < 0.01) was associated with an increased rate of opportunistic infections. However, the use of infliximab was not associated with an increased rate of opportunistic infections (p = 0.62). Multivariate analysis indicated that the use of thiopurine was an independent risk factor for opportunistic infections (p < 0.01).
Age ≥50 years and the use of immunosuppressants are risk factors for opportunistic infections in patients with IBD. In our cohort, tuberculosis was not seen as a complication of immunosuppressant therapy.
- Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549–58. CrossRef
- Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2009;3:47–91. CrossRef
- Kollas G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002;13:315–21. CrossRef
- Duchet-Niedziolka P, Coutsinos Z, Hanslik T. Anti-TNFα therapy and vaccine of adults. Joint Bone Spine. 2007;74:563–5. CrossRef
- Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36. CrossRef
- Naganuma M, Fujii T, Kunisaki R, Yoshimura N, Takazoe M, Takeuchi Y, et al. Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohns Colitis. 2012 (epub ahead of print).
- Naganuma M, Kunisaki R, Yoshimura N, Nagahori M, Yamamoto H, Kimura H, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohn’s Colitis. 2011;5:317–23. CrossRef
- Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohn’s Colitis. 2008;2:315–21. CrossRef
- Hammer SM. Clinical practice: management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702–10. CrossRef
- Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–37. CrossRef
- Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30. CrossRef
- D’Haens G, Colombel JF, Hommes DW. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology. 2008;134:A140.
- Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33. CrossRef
- Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64:2763–92. CrossRef
- Fillet AM. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients. Drugs Aging. 2002;19:343–54. CrossRef
- Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2012 (epub ahead of print).
- Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5. CrossRef
- Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837–46. CrossRef
- Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90–6. CrossRef
- Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumour necrosis factor α therapies in elderly patients with rheumatoid arthritis. Arthr Rheum. 2007;57:679–85. CrossRef
- Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthr Rheum. 2007;56:1754–64. CrossRef
- A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease
Journal of Gastroenterology
Volume 48, Issue 5 , pp 595-600
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Inflammatory bowel disease
- Opportunistic infection
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology and Hepatology, School of Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
- 2. Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
- 3. IBD Center, Yokohama City University Medical Center, Yokohama, Japan
- 4. IBD Center, Social Insurance Central General Hospital, Tokyo, Japan
- 5. Department of Gastroenterology and Hepatology, Showa University, Tokyo, Japan